Alain C. Mita

11.4k total citations · 3 hit papers
210 papers, 8.1k citations indexed

About

Alain C. Mita is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alain C. Mita has authored 210 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 122 papers in Oncology, 85 papers in Molecular Biology and 67 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alain C. Mita's work include Lung Cancer Treatments and Mutations (36 papers), Cancer Treatment and Pharmacology (36 papers) and Head and Neck Cancer Studies (23 papers). Alain C. Mita is often cited by papers focused on Lung Cancer Treatments and Mutations (36 papers), Cancer Treatment and Pharmacology (36 papers) and Head and Neck Cancer Studies (23 papers). Alain C. Mita collaborates with scholars based in United States, France and United Kingdom. Alain C. Mita's co-authors include Monica Mita, Francis J. Giles, Steffan T. Nawrocki, Eric K. Rowinsky, Anthony W. Tolcher, Devalingam Mahalingam, Kamalesh K. Sankhala, Allen S. Ho, Zachary S. Zumsteg and Stephen L. Shiao and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Alain C. Mita

201 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

2008 638 citations Alain C. Mita, Monica Mita et al. Clinical Cancer Research profile →
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

2017 466 citations Jeffrey R. Infante, Alain C. Mita et al. Journal of Clinical Oncology profile →
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

2019 319 citations Michael S. Gordon, Alain C. Mita et al. profile →

Peers

Countries citing papers authored by Alain C. Mita

Since Specialization

Citations

This map shows the geographic impact of Alain C. Mita's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alain C. Mita with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alain C. Mita more than expected).

Fields of papers citing papers by Alain C. Mita

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alain C. Mita. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alain C. Mita. The network helps show where Alain C. Mita may publish in the future.

Co-authorship network of co-authors of Alain C. Mita

This figure shows the co-authorship network connecting the top 25 collaborators of Alain C. Mita. A scholar is included among the top collaborators of Alain C. Mita based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alain C. Mita. Alain C. Mita is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Baseline weight recovery and mortality risk in head and neck cancer 2024 ·Head & Neck ·(unknown), (unknown), (unknown), (unknown), Michael Luu, (unknown), (unknown), (unknown), (unknown), Julie K. Jang, Alain C. Mita, Kevin S. Scher, Justin T. Moyers, Jon Mallen‐St. Clair, Evan Walgama, Zachary S. Zumsteg, Allen S. Ho	1
2	Abstract PO4-18-07: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in triple negative breast cancer and transcriptionally addicted relapsed or refractory solid tumors 2024 ·Cancer Research ·Monica Mita, Alain C. Mita, Miguel A. Villalona‐Calero, Noah Federman, Drew Rasco, David R. Spigel, Jia Luo, Gregory M. Coté, Richard E. Cutler, Pavan Kumar, Crystal MacKenzie, Charles Y. Lin, Jorge DiMartino, Elizabeth Olek, Brian A. Van Tine	1
3	Abstract CT066: Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53 2024 ·Cancer Research ·Ecaterina E. Dumbrava, Fábio M. Iwamoto, Mark Agulnik, Mohammed Milhem, Anthony W. Tolcher, Rashmi Chugh, Michael J. Demeure, Alain C. Mita, (unknown), Mark S. Diamond, Beloo Mirakhur, (unknown), Aram Oganesian, (unknown), Harold Keer, Jason Taylor, Martin Sims, Andrea Biondo, Simone Jueliger, Alexander I. Spira	1
4	627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma 2023 ·SHILAP Revista de lepidopterología ·Jordi Rodon, Marya Chaney, Justine V. Cohen, Tina Garyantes, (unknown), Jeffrey J. Ishizuka, Alain C. Mita, Monica Mita, Carolyn Y. Muller, Christopher A. Natale, Marlana Orloff, Kyriakos P. Papadopoulos, Sapna P. Patel, Alexander N. Shoushtari	0
5	Comparative impact of grade on mortality across salivary cancers: A novel, unifying staging system 2023 ·Head & Neck ·Allen S. Ho, Michael Luu, Bonnie Balzer, Katri Aro, Julie K. Jang, Alain C. Mita, Kevin S. Scher, Jon Mallen‐St. Clair, (unknown), (unknown), Joel B. Epstein, De‐Chen Lin, Michelle Chen, Zachary S. Zumsteg	8
6	Predicting Pathologic Lymph Node Positivity in cN0 Pharynx and Larynx Cancers 2022 ·The Laryngoscope ·Eric M. Anderson, Michael Luu, Diana J. Lu, (unknown), (unknown), Kevin S. Scher, Alain C. Mita, Jon Mallen‐St. Clair, Allen S. Ho, Zachary S. Zumsteg	2
7	A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma 2020 ·Clinical Cancer Research ·Monica Mita, Patricia LoRusso, Kyriakos P. Papadopoulos, Michael S. Gordon, Alain C. Mita, Roberta Ferraldeschi, Harold Keer, Aram Oganesian, Xiang Yao Su, Simone Jueliger, Anthony W. Tolcher	30
8	Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer 2020 ·Targeted Oncology ·Eric Vail, Jianbo Song, Jing Xu, (unknown), (unknown), (unknown), Rhona Schreck, (unknown), Wenjuan Zhang, Serhan Alkan, Alain C. Mita, Monica Mita, Robert A. Figlin, David M. Engman, Jean Lopategui	9
9	Variations in the association of grade with survival across the head and neck cancer landscape 2020 ·Head & Neck ·Eric M. Anderson, Michael Luu, Bonnie Balzer, Kevin S. Scher, Alain C. Mita, Diana J. Lu, Stephen L. Shiao, Jon Mallen‐St. Clair, Allen S. Ho, Zachary S. Zumsteg	13
10	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors 2019 ·Clinical Cancer Research ·Rastislav Bahleda, Antoîne Italiano, Cinta Hierro, Alain C. Mita, Andrés Cervantes, Nancy Chan, Mark M. Awad, Emiliano Calvo, Víctor Moreno, Ramaswamy Govindan, Alexander I. Spira, (unknown), Bob Zhong, (unknown), Italo Poggesi, Trilok Parekh, Hong Xie, Jeffrey R. Infante, Josep Tabernero	187
11	Stage I HPV‐positive oropharyngeal cancer: Should all patients receive similar treatments? 2019 ·Cancer ·Emi Yoshida, Michael Luu, Jon Mallen‐St. Clair, Alain C. Mita, Kevin S. Scher, Diana J. Lu, Anthony T. Nguyen, Stephen L. Shiao, Allen S. Ho, Zachary S. Zumsteg	9
12	Quantitative survival impact of composite treatment delays in head and neck cancer 2018 ·Cancer ·Allen S. Ho, Sungjin Kim, Mourad Tighiouart, Alain C. Mita, Kevin S. Scher, Joel B. Epstein, Anna Laury, Ravi S. Prasad, Nabilah Ali, Chrysanta Patio, Jon Mallen‐St. Clair, Zachary S. Zumsteg	71
13	Quantitative lymph node burden as a ‘very-high-risk’ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation 2018 ·Annals of Oncology ·Zachary S. Zumsteg, Michael Luu, (unknown), Mourad Tighiouart, Alain C. Mita, Kevin S. Scher, Diana J. Lu, Stephen L. Shiao, Jon Mallen‐St. Clair, Allen S. Ho	30
14	Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors 2016 ·Clinical Cancer Research ·Daniel D. Von Hoff, Monica Mita, Ramesh K. Ramanathan, Glen J. Weiss, Alain C. Mita, Patricia LoRusso, Howard A. Burris, Lowell L. Hart, Susan C. Low, Donald M. Parsons, Stephen E. Zale, Jason M. Summa, Hagop Youssoufian, Jasgit C. Sachdev	215
15	A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Jordi Rodón, Hussein Tawbi, Anne Thomas, Ronald G. Stoller, Christian P. Turtschi, José Baselga, John Sarantopoulos, Devalingam Mahalingam, Yaping Shou, Melissa A. Moles, Lin Yang, Camille Granvil, Eunju Hurh, Kristine Rose, Dereck D. Amakye, Reinhard Dummer, Alain C. Mita	187
16	Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 2012 ·Clinical Cancer Research ·José Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Federico Rojo, Josep Tabernero, Clifford DiLea, William Mietlowski, (unknown), (unknown), Margaret Dugan, Kathryn Parker, Eric Walk, A. van Oosterom, Erika Martinelli, Chris H. Takimoto	14
17	Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Lee S. Rosen, Igor Puzanov, Gregory Friberg, Emily Chan, Yuying C. Hwang, Hongjie Deng, Jill Gilbert, Devalingam Mahalingam, Ian McCaffery, (unknown), Alain C. Mita, Monica Mita, Marilyn Mulay, (unknown), Min Zhu, John Sarantopoulos	30
18	Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin 2011 ·Clinical Cancer Research ·Anthony W. Tolcher, Christopher J. Sweeney, K. Papadopoulos, Amita Patnaik, E. Gabriela Chiorean, Alain C. Mita, Kamalesh K. Sankhala, Eric S. Furfine, Jochem Gokemeijer, Lisa Iacono, Cheryl A. Eaton, Bruce A. Silver, Monica Mita	67
19	A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies 2009 ·Clinical Cancer Research ·Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy S. Chu, Nancy Wong, Christopher DesJardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, Chris H. Takimoto	121
20	Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies 2008 ·Journal of Clinical Oncology ·Monica Mita, Alain C. Mita, Quincy S. Chu, Eric K. Rowinsky, Gerald J. Fetterly, (unknown), Amita Patnaik, Lesley Mathews, Alejandro D. Ricart, Theresa A. Mays, Heather Knowles, Victor M. Rivera, (unknown), Camille L. Bedrosian, Anthony W. Tolcher	227

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact